GD2-SADA is under clinical development by Y-mAbs Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GD2-SADA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GD2-SADA overview
Monoclonal antibody conjugate is under development for the treatment of GD-2 positive solid tumor including neuroblastoma, small cell lung cancer, sarcoma and malignant melanoma. The drug contains anti-GD2 antibody conjugated to radioactive payload. It is being developed based on pre-targeted radioimmunotherapy platform SADA (Self-Assembly and DisAssembly) technology. It is administered through intravenous route.
Y-mAbs Therapeutics overview
Y-mAbs Therapeutics(Y-mAbs) is a clinical biopharmaceutical company that develops and commercializes novel antibody therapeutic products for cancer treatment. The company technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its pipeline products include DANYELZA (naxitamab-gqgk) treats relapsed and refractory high-risk neuroblastoma, front-line induction in high-risk neuroblastoma, relapsed second-line osteosarcoma, chemoimmunotherapy for relapsed and refractory high-risk neuroblastoma; GD2-SADA for solid tumors (SCLC, malignant melanoma, sarcoma);
For a complete picture of GD2-SADA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
